The FDA has updated the label of Novo Nordisk’s type 2 diabetes drug Ozempic, or semaglutide, which is also used for weight loss, to acknowledge reports of ileus or intestinal blockage in some people using the drug. “Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure," the label says.
